Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk: Results from the EPIC cohort

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined. Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression. Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both. Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types. Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC.


  • Daniel W. Cramer
  • Raina N. Fichorova
  • Kathryn L. Terry
  • Hidemi Yamamoto
  • Allison F. Vitonis
  • Eva Ardanaz
  • Dagfinn Aune
  • Heiner Boeing
  • Marie Christine Boutron-Ruault
  • Maria Dolores Chirlaque
  • Miren Dorronsoro
  • Laure Dossus
  • Eric J. Duell
  • Inger T. Gram
  • Marc Gunter
  • Louise Hansen
  • Annika Idahl
  • Theron Johnson
  • Kay Tee Khaw
  • Vittorio Krogh
  • Marina Kvaskoff
  • Amalia Mattiello
  • Giuseppe Matullo
  • Melissa A. Merritt
  • Philippos Orfanos
  • N. Charlotte Onland-Moret
  • Domenico Palli
  • Eleni Peppa
  • J. Ramon Quiros
  • Maria Jose Sanchez-Perez
  • Gianluca Severi
  • Anne Tjønneland
  • Ruth C. Travis
  • Antonia Trichopoulou
  • Rosario Tumino
  • Elisabete Weiderpass
  • Renee T. Fortner
  • Rudolf Kaaks
Enheter & grupper
Externa organisationer
  • Brigham and Women's Hospital / Harvard Medical School
  • Harvard Medical School
  • Harvard University
  • Health Research Institute of Navarra (IDISNA)
  • CIBER Epidemiology and Public Health (CIBERESP)
  • Imperial College London
  • German Institute of Human Nutrition
  • Skåne University Hospital
  • University of Murcia
  • International Agency for Research on Cancer, World Health Organization
  • Catalan Institute of Oncology
  • UiT The Arctic University of Norway, Tromsø
  • Danish Cancer Society Research Center
  • Umeå University
  • German Cancer Research Centre
  • University of Cambridge
  • Istituto Nazionale dei Tumori
  • University of Naples Federico II
  • University of Turin
  • Hellenic Health Foundation, Athens
  • National and Kapodistrian University of Athens
  • University Medical Center Utrecht
  • Cancer Research and Prevention Institute
  • Public Health Directorate
  • University of Oxford
  • Folkhälsans forskningscentrum
  • Cancer Registry of Norway Institute of Population-Based Cancer Research
  • Karolinska Institute

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Miljömedicin och yrkesmedicin
Sidor (från-till)790-804
Antal sidor15
TidskriftCancer Epidemiology Biomarkers and Prevention
Utgåva nummer7
StatusPublished - 2018 jul 1
Peer review utfördJa